These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27639083)

  • 21. Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
    Ureña Torres PA; Bover J; Cohen-Solal M
    Drugs Today (Barc); 2017 Sep; 53(9):489-500. PubMed ID: 29238762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients
.
    Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Fujii A; Odani M; Akizawa T
    Clin Nephrol; 2017 Aug; 88(2):68-78. PubMed ID: 28671062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.
    Yu L; Tomlinson JE; Alexander ST; Hensley K; Han CY; Dwyer D; Stolina M; Dean C; Goodman WG; Richards WG; Li X
    Calcif Tissue Int; 2017 Dec; 101(6):641-653. PubMed ID: 29038882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
    Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
    Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism.
    Fielden MR; Dean C; Black K; Sawant SG; Subramanian R; Tomlinson JE; Walter S; Zimmermann C; Griggs MW; McKeon ME; Lewis EM; Beevers C; Pyrah I
    Int J Toxicol; 2016 May; 35(3):294-308. PubMed ID: 26941242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Etelcalcetide: First Global Approval.
    Blair HA
    Drugs; 2016 Dec; 76(18):1787-1792. PubMed ID: 27900648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.
    Ye J; Deng G; Gao F
    Drug Des Devel Ther; 2018; 12():901-909. PubMed ID: 29719376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with CKD-MBD on Hemodialysis: A Nephrology Nursing Perspective.
    Hain D; Tomlin H; Gibson C
    Nephrol Nurs J; 2019; 46(3):315-290. PubMed ID: 31199098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Więcek A
    Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
    Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
    Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etelcalcetide versus placebo for secondary hyperparathyroidism in patients receiving hemodialysis: A meta-analysis of randomized controlled trials.
    Zhu Y; Ou J; Liu X; Xie Z
    Clin Nephrol; 2020 Oct; 94(4):173-180. PubMed ID: 32729818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor.
    Bushinsky DA; Block GA; Martin KJ; Bell G; Huang S; Sun Y; Spiegel DM; Walsh L; Mix TC; Kewalramani R
    Am J Nephrol; 2015; 42(5):379-88. PubMed ID: 26684933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study.
    Honda H; Koiwa F; Ogata H; Shishido K; Sekiguchi T; Michihata T; Ogawa H; Mukai M; Takahashi K; Suzuki R; Kino K; Kato K; Yamamoto K; Kinugasa E; Akizawa T
    Int J Clin Pharmacol Ther; 2014 May; 52(5):360-8. PubMed ID: 24569127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.